Detailed price information for Prime Medicine Inc (PRME-Q) from The Globe and Mail including charting and trades.
Few companies stand better poised than Beam Therapeutics to reap the first fruits of the FDA’s promised flexibility toward cell and gene therapies. | Riding a regulatory win for its base editing ...
A profound transformation is taking place in therapeutic discovery, development, and delivery.2026 will be a pivotal year for ...
CAMBRIDGE, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic ...
Scribe Therapeutics, Inc. (Scribe), a biotechnology company pioneering highly engineered CRISPR technologies designed to reshape the treatment of disease by enabling earlier intervention, improved ...
Astellas Gene Therapies remains intent on treating X-linked Myotubular Myopathy (XLMTM) through a gene therapy—but instead of AAV-based resamirigene bilparvovec (AT132), Astellas is now partnering ...
By Ariba Shahid and Mohammed Waseem KARACHI, Jan 19 (Reuters) - Pakistani firefighters began pulling bodies from the ...
From Sinners to One Battle After Another (both of which received over 10 nominations), the competition is intense. The ceremony airs on Sunday, March 15, at 7 p.m. ET/4 p.m. PT, giving you plenty of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results